Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick Lansigan

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Blood Advances|February 5, 2024
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective studyLaura Samples, Jenna Voutsinas, Bita Fakhri, et al.
Blood|December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapyAnthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.
The Oncologist|April 11, 2020
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin LymphomaReid W Merryman, Nicole A Carreau, Ranjana H Advani, et al.
Blood Advances|January 17, 2020
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsPallawi Torka, Shalin K Kothari, Suchitra Sundaram, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2017
Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United StatesEric D Hsi, Steven M Horwitz, Kenneth R Carson, et al.
American Journal of Hematology|August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trialAnthony R Mato, Lindsey E Roeker, John N Allan, et al.
American Journal of Hematology|December 19, 2024
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World StudyNilanjan Ghosh, Toby A Eyre, Jennifer R Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete RemissionDaniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, et al.
Blood Advances|June 23, 2022
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimenMeghan C Thompson, Rosemary A Harrup, Catherine C Coombs, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Blood Advances|February 5, 2024
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective studyLaura Samples, Jenna Voutsinas, Bita Fakhri, et al.
Blood|December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapyAnthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.
The Oncologist|April 11, 2020
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin LymphomaReid W Merryman, Nicole A Carreau, Ranjana H Advani, et al.
Blood Advances|January 17, 2020
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsPallawi Torka, Shalin K Kothari, Suchitra Sundaram, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2017
Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United StatesEric D Hsi, Steven M Horwitz, Kenneth R Carson, et al.
American Journal of Hematology|August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trialAnthony R Mato, Lindsey E Roeker, John N Allan, et al.
American Journal of Hematology|December 19, 2024
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World StudyNilanjan Ghosh, Toby A Eyre, Jennifer R Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete RemissionDaniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, et al.
Blood Advances|June 23, 2022
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimenMeghan C Thompson, Rosemary A Harrup, Catherine C Coombs, et al.
Pageof 9